Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

Mohammed A. Aljama, M. Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Eli Muchtar, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson I. Gonsalves, Rahma Warsame, Taxiarchis V. Kourelis, Yi Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S. GoRobert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (.0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P 5 .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P, .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.

Original languageEnglish (US)
Pages (from-to)3149-3154
Number of pages6
JournalBlood Advances
Volume2
Issue number22
DOIs
StatePublished - Nov 27 2018

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma'. Together they form a unique fingerprint.

  • Cite this